萬達生物製藥 VNDA 深 滬
等待開盤 10-30 09:30:00 美东时间
5.41
-0.170
-3.05%
華盛通- 最 高5.63
- 今 開5.63
- 成交量 106.35万股
- 最 低 5.21
- 昨 收 5.58
- 總市值 3.20亿
- 52周最高 5.70
- 市盈率 靜 --
- 換手率 1.80%
- 52周最低 3.8092
- 委 比 -86.86%
- 總股本 5908.91万
- 歷史最高 33.44
- 量 比 1.83
- 振 幅 7.53%
- 歷史最低 2.92
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vanda Pharmaceuticals Narrows FY2025 Sales Guidance from $210.000M-$250.000M to $210.000M-$230.000M vs $224.977M Est
Vanda Pharmaceuticals (NASDAQ:VNDA) narrows FY2025 sales outlook from $210.000 million-$250.000 million to $210.000 million-$230.000 million vs $224.977 million estimate.
今天 04:02
Earnings Scheduled For October 29, 2025
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
Jim Cramer Calls Cameco A Good Company, Recommends Buying This Financial Stock
On CNBC's "Mad Money Lightning Round," Jim Cramer discussed Apollo Global, National Fuel Gas, Main Street Capital and Vanda Pharmaceuticals.
10-27 20:05
Vanda Pharmaceuticals Reaches Agreement with FDA
Vanda ( ($VNDA) ) has issued an update. On October 1, 2025, Vanda Pharmaceutica...
10-02 05:27
Vanda Pharmaceuticals Announced The Publication Of An Article Titled "Melatonin Agonist Tasimelteon Improves Sleep In Patients With Primary Insomnia: A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial" In PLOS One, A Leading Open-Access Journal
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the publication of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" in PLOS One, a leading open-access journal.1
09-25 20:08
Vanda Pharmaceuticals gets FDA orphan drug status for VGT-1849B
Vanda Pharmaceuticals (NASDAQ:VNDA) said that the U.S. FDA has granted orphan drug designation for its experimental drug candidate, VGT-1849B, for the treatment of polycythemia vera. With its orphan d...
08-28 22:08
Vanda asks FDA's Makary to review approval of Hetlioz generics
Vanda Pharmaceuticals (NASDAQ:VNDA) has formally asked U.S. FDA Commissioner Marty Makary to review the recently retired director of the Center for Drug Evaluation and Research's decision to uphold th...
08-22 05:35
Vanda Wins Major Court Battle For Jet Lag Drug, Forcing FDA To Revisit Rejection
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug Administration (FDA) in its longstanding dispute with the agency regarding the approvability
08-18 19:08
中信证券：首予阜博集团“买入”评级 目标价8港元 看好全球维持版权保护长期需求
中信证券发布研报称，看好阜博集团（03738）投资价值公司，首次覆盖，给予“买入”评级。预计公司2025-2027年收入分别为29.79/37.38/47.1...
08-14 15:07
Vanda Pharmaceuticals Affirms FY2025 Sales Guidance of $210.00M-$250.00M vs $227.72M Est
Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2025 sales outlook from $210.00 million-$250.00 million to $210.00 million-$250.00 million vs $227.72 million estimate.
07-31 19:37
